Mid
M
MRKAI Stock Diagnostic Report
Merck pulls BLA for antibody-drug conjugate I-DXd for small cell lung cancer
Merck's withdrawal of the BLA for its small cell lung cancer drug candidate I-DXd has increased uncertainty in its pipeline development.
View Source Article ↗
AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
MRK Analysis History (Last 30 Days)